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ABSTRACT
Small intestinal neuroendocrine tumours (NETs) are rare malignancies that occur in the small intestine.
The incidence of small intestinal NETs has increased substantially in recent decades. Similar to that of gen-
eral NETs, the diagnosis rate of small intestinal NETs is increasing continuously. Small intestinal NETs often
metastasize to the lymph nodes, even when the lesions are small. Surgical resection of the primary tumour
and associated mesenteric lymph nodes is recommended. We present a case of a NET in the ileum that was
incidentally diagnosed along with large mesenteric lymph node metastasis. Abdominal computed tomogra-
phy for examination of urinary frequency revealed an intra-abdominal mass, measuring 80 mm in diameter.
The patient was intraoperatively diagnosed with an ileocaecal mesenteric mass, and ileocaecal resection with
lymph node dissection was performed. The resected specimen incidentally showed a NET measuring 14 mm
in diameter in the ileum, located 90 cm from the ileocaecal valve. The ileocaecal mesenteric mass was histo-
pathologically diagnosed as lymph node metastasis of the NET. This case confirms the importance of making
an immediate intraoperative pathological diagnosis and performing a thorough examination of small intesti-
nal lesions when a large mesenteric tumour is suspected.
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INTRODUCTION
Neuroendocrine tumours (NETs) are uncommon
tumours developing from the neuroendocrine cells in the
body. Most NETs occur in the gastrointestinal tract1).
Small intestinal NETs are rare and slow growing and
develop from the enterochromaffin cells found in the
crypts of Lieberkuhn. Cases of small intestinal NETs are
extremely rare in Japan, accounting for only 2.9% of all
reported cases of NETs7). Nevertheless, the incidence of
small intestinal NETs is increasing continuously, and
these tumours are associated with the presence of mes-
enteric lymph node metastases at diagnosis in 88% of
patients13). A 2-cm tumour size is generally considered
the cut-off point for the risk of lymph node metastasis in
intestinal NETs without other high-risk features; how-
ever, metastatic disease has been reported in 12% of
tumours in the jejunum and ileum measuring ≤ 1 cm20).
The goals of treatment are to resect the primary tumour
and associated regional lymph nodes and control NET
syndromes, when present3).
CASE PRESENTATION
A 79-year-old male patient was referred to our hospi-
tal for the evaluation of urinary frequency. He had a his-
tory of acute myocardial infarction but no history of
previous abdominal surgery or trauma. His abdomen
was soft, with a palpable mass in the right hypogastric
region. The patient’s haemoglobin concentration was
slightly low (10.9 g/dl), but his white blood cell count,
platelet count, and C-reactive protein level were within
normal limits. Tumour marker levels were also within
normal ranges, (carcinoembryonic antigen, 2.2 ng/ml
and cancer antigen 19-9, 15.4 U/ml). The level of soluble
interleukin-2 receptor was moderately high at 959 U/ml.
Dynamic computed tomography (CT) showed a lobular,
heterogeneous intra-abdominal mass measuring 80 × 70
× 60 mm in diameter (Figure 1). The mass was enhanced
in the arterial phase. Upper gastrointestinal endoscopy
and colonoscopy showed no evidence of tumour.
Although fluorodeoxyglucose-positron emission tomog-
raphy/CT (FDG-PET/CT) revealed accumulation of FDG
in the tumour (maximum standardized uptake value,
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2.8), we could not find the primary lesion (Figure 2).
As a preoperative diagnosis, we suspected stromal
tumour, leiomyoma, lymphoma, or NET; exploratory
laparotomy was performed to confirm the diagnosis.
Laparotomy revealed a movable tumour measuring 80
mm in diameter located within the ileocaecal mesentery.
Combined ileocaecal resection, including the terminal
ileum 130 cm from the ileocaecal valve, was mandatory
to remove the tumour. The resected specimen showed a
mesenteric tumour and incidentally showed a sharply
demarcated mass with a central depression measuring
14 mm in diameter, in the ileum located 90 cm from the
ileocaecal valve (Figure 3).
Histological analysis of the resected specimen and
immunochemical analysis confirmed the diagnosis of G1
NET in the ileum (positive for chromogranin A and syn-
aptophysin; absence of necrosis; mitotic count of 3/10
high-power fields; Ki-67 labelling index < 1%). The anal-
ysis also confirmed the large mesenteric lymph node as a
Figure 2 Positron emission tomography/computed tomog-
raphy (PET/CT) revealed accumulation of fluorodeoxyglucose
in the tumour (maximum standardized uptake value, 2.8).
NET metastasis (Figure 4A–D).
The increased urinary frequency, which had been the
patient’s preoperative complaint, was immediately
improved after the surgery, and there has been no
relapse thus far.
DISCUSSION
Gastrointestinal neuroendocrine neoplasms (GI-
NENs), originating from amine precursor uptake and
decarboxylation cells in the digestive tract, have the abil-
ity to undergo multiple differentiations and secrete vari-
ous active hormones, leading to significant differences in
biological behaviours and prognoses10).
The World Health Organization’s Classification of
Tumours in the Digestive System revised the denomina-
tion and classification for GI-NENs, dividing them into
NET, neuroendocrine carcinoma, mixed adenoneuroen-
docrine carcinoma, hyperplasia, and pre-neoplasm. The
Figure 3 The resected specimen showing the mass in the
ileocaecal mesentery and a mass measuring 14 mm in diameter
in the ileum, 90 cm from the ileocaecal valve (white circle).
Figure 1 Abdominal computed tomography (CT) with contrast showing a lobular, heterogeneous mass measuring 80 × 70 × 60
mm in diameter. The mass was slightly heterogeneously enhanced (A). Coronal CT image showing that the feeding artery of the
mass was a branch of the superior mesenteric artery and ileocolic artery situated in the cranial surface of the mass.
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majority of NETs are found within the gastrointestinal
tract (55%) and bronchopulmonary system (30%)11). The
differences in incidence rates by race are striking21). For
NETs in the jejunum and ileum, the reported incidence
rates among Caucasian, African American, and Asian/
Paciﬁc Islander patient groups are 0.71, 0.88, and 0.09
per 100,000, respectively21). Cases of small intestinal
NETs are extremely rare in Japan, accounting for only
2.9% of all reported cases of NETs7).
Kulke et al. stated that 75% of small intestinal NETs
occur in the distal ileum, within 60 cm of the ileocaecal
valve8). Patients are commonly diagnosed during an
operation conducted for some other reason. The discov-
ery of these tumours often occurs as a result of surgical
exploration for chronic blood loss, intestinal obstruction,
or during the course of metastatic disease evaluation.
Regardless of how they are found, the discovery of a pri-
mary NET should engender a diligent search for other
tumours because they are often small and numerous2).
Small intestinal NETs are associated with the presence
of mesenteric lymph node metastases at diagnosis in
88% of patients13). Tumour size has the greatest effect on
the frequency of metastatic disease during the operation.
The relationship between tumour size and the occur-
rence of metastases was investigated in a series by Moer-
tel et al., which showed a metastatic rate of 2% for
tumours with diameter < 1 cm, 50% for tumours 1–2 cm
in diameter, and 80% for tumours with diameter > 2 cm12).
The incidence of NETs is increasing, which is thought
to be largely associated with the introduction of more
sensitive diagnostic tools. However, lesions < 2 cm can
be difficult to detect, especially within the alimentary
canal, where they may not cause any symptoms, such as
obstruction. This makes localization of small bowel NET
and diagnosis challenging in clinical practice. These
tumours cannot be found using upper gastrointestinal
Figure 4 Histopathological findings. (A) The mass com-
prised neuroendocrine tumour cells invading the muscular
layer of the intestinal proper (haematoxylin and eosin, origi-
nal magnification ×100). (B) The mesenteric lymph node also
comprised neuroendocrine tumour cells. (C) Immunoreactivi-
ty for chromogranin A in tumour cells. (D) Immunochemistry
showing a mitotic count of 3/10 high-power fields, suggesting
Ki-67 labelling index of < 1%.
endoscopy or colonoscopy; one study reported a diagnos-
tic yield of only 45% in the identiﬁcation of primary
small intestinal NETs using video capsule endoscopy19).
The sensitivity in detecting multiple NETs with these
imaging methods remains low. Locally advanced disease
with typical mesenteric involvement can be identified
using abdominal CT scans as an ill-defined mass at the
root of the mesentery, with characteristic radiating of
dense soft tissue strands, forming thickened neurovascu-
lar bundles18). Recently, integrated FDG-PET/CT has
been demonstrated to be an effective tool for differentiat-
ing malignant from benign lesions22). Although NETs,
especially in the typical form, have a low metabolic activ-
ity that reduces the sensitivity of FDG-PET/CT in diag-
nosing these neoplasms4), only tumours with high
proliferative activity and low differentiation may show
increased accumulation of FDG17). Differential diagnosis
of a large mesenteric lymph node should include gastro-
intestinal stromal tumour, malignant lymphoma, granu-
loma, malignant peritoneal mesothelioma (MPM), and
mesenteric fibromatosis. A granuloma has no contrast
effect on CT scan. Several reports of CT ﬁndings of MPM
exist, including diffuse omental masses, mesenteric nod-
ules, or parietal peritoneal thickening, with or without
ascites16). It is difficult to make a differential diagnosis
for these neoplasms because there are no specific
imaging features. Deﬁnitive diagnosis is made by histo-
pathology.
Goals of treatment are to resect the primary tumour
and associated regional lymph nodes and to manage
NET syndromes, when present3). Surgical removal of the
tumour is curative in localized disease, although finding
a small primary lesion is challenging. The goal of surgery
in midgut NETs is complete, curative, en bloc resection
of the primary tumour and extensive mesenteric lymph
node dissection. Currently, no studies have provided a
gold standard in the lymphadenectomy procedure
required for small intestinal NETs. Hellman et al. sug-
gested that resection of the primary tumour and mesen-
teric lymph node metastasis improves survival6). Landry
et al. reported that regional mesenteric lymphadenec-
tomy, with resection of at least seven lymph nodes, is
associated with improved survival9). The American Joint
Committee on Cancer in 2010 revealed that the progno-
sis of small intestinal NETs is poor, with a 5-year sur-
vival rate of approximately 60% in the United States.
However, with regard to prognosis, patients with R0
resection in small intestinal malignancy have signifi-
cantly high survival rates1,15).
In this case, the entire primary lesion and lymph node
metastasis in the mesentery were fortunately resected,
and the prognosis is likely good. Although abdominal
contrast-enhanced CT revealed only the intra-abdominal
tumour and the primary lesion was not detected before
and during surgery, it was incidentally detected on the
cut surface. It was difficult in the present case to diag-
nose the primary lesion, so it might have been better to
perform an immediate intraoperative pathological diag-
nosis of the mesenteric tumour, to detect the primary
tumour during the surgery.
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Various studies have shown that, in many respects,
somatostatin receptor-based PET/CT is clearly superior
to the standard cross-sectional imaging with CT or mag-
netic resonance imaging in the detection of G1 and G2
NETs, a finding that has influenced therapeutic strat-
egies. The diagnostic sensitivity of octreoscan ranges
between 80% and 90%5); this technology can also be used
as a follow-up tool. Pasquer et al. reported that 61% of
multiple tumours were missed during preoperative pro-
cedures14). Therefore, surgeons should explore and pal-
pate the entire small bowel to detect all possible small
intestinal NETs, given the possibility that they may exist
as small or multiple lesions.
CONCLUSION
Small intestinal NETs are rare in Japan. NETs some-
times metastasise to a lymph node that is larger than the
primary lesion, even though the NET may be too small to
diagnose. In case of a large mesenteric mass, an intrao-
perative pathological diagnosis and thorough examina-
tion for small intestinal lesions before and during
surgery should be performed.
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